G. Dresemann

1000 total citations
15 papers, 619 citations indexed

About

G. Dresemann is a scholar working on Genetics, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. Dresemann has authored 15 papers receiving a total of 619 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 9 papers in Hematology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Dresemann's work include Glioma Diagnosis and Treatment (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Myeloid Leukemia Research (6 papers). G. Dresemann is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Myeloid Leukemia Research (6 papers). G. Dresemann collaborates with scholars based in Germany, United States and Switzerland. G. Dresemann's co-authors include David A. Reardon, Annick Desjardins, James E. Herndon, Jennifer A. Quinn, James J. Vredenburgh, Kimberly Kicielinski, Jeremy N. Rich, August J. Salvado, Merrill J. Egorin and James M. Provenzale and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

G. Dresemann

13 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Dresemann Germany 7 417 227 157 142 126 15 619
Michael Badruddoja United States 8 387 0.9× 238 1.0× 160 1.0× 152 1.1× 167 1.3× 20 681
Nathan De Beule Belgium 11 302 0.7× 252 1.1× 100 0.6× 120 0.8× 170 1.3× 22 747
August J. Salvado United States 13 523 1.3× 291 1.3× 169 1.1× 147 1.0× 153 1.2× 37 885
Koji Oka Japan 9 351 0.8× 310 1.4× 195 1.2× 138 1.0× 227 1.8× 23 727
Katharina Seystahl Switzerland 16 434 1.0× 230 1.0× 147 0.9× 196 1.4× 192 1.5× 40 867
Wolfgang Wick Germany 10 312 0.7× 252 1.1× 150 1.0× 136 1.0× 112 0.9× 17 665
Christopher J. Pirozzi United States 12 255 0.6× 374 1.6× 246 1.6× 105 0.7× 101 0.8× 25 689
Candice A. Romany United States 5 259 0.6× 357 1.6× 150 1.0× 55 0.4× 123 1.0× 8 661
Sandra H. E. Sprenger Netherlands 12 239 0.6× 257 1.1× 205 1.3× 126 0.9× 93 0.7× 13 538
Paulo Salazar United States 10 187 0.4× 236 1.0× 187 1.2× 113 0.8× 286 2.3× 11 559

Countries citing papers authored by G. Dresemann

Since Specialization
Citations

This map shows the geographic impact of G. Dresemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Dresemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Dresemann more than expected).

Fields of papers citing papers by G. Dresemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Dresemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Dresemann. The network helps show where G. Dresemann may publish in the future.

Co-authorship network of co-authors of G. Dresemann

This figure shows the co-authorship network connecting the top 25 collaborators of G. Dresemann. A scholar is included among the top collaborators of G. Dresemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Dresemann. G. Dresemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Dresemann, G.. (2010). Temozolomide in malignant glioma. OncoTargets and Therapy. 3. 139–139. 28 indexed citations
2.
Paulsson, Janna, Maja Bradic Lindh, Malin Jarvius, et al.. (2010). Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma. International Journal of Cancer. 128(8). 1981–1988. 41 indexed citations
3.
Reardon, David A., G. Dresemann, Sophie Taillibert, et al.. (2009). Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. British Journal of Cancer. 101(12). 1995–2004. 100 indexed citations
4.
5.
Pursche, Stefan, Eberhard Schleyer, Malte von Bonin, et al.. (2008). Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients. Current Clinical Pharmacology. 3(3). 198–203. 47 indexed citations
6.
Dresemann, G., G. Kautz, & H. Bünte. (2008). Langzeitergebnisse nach endoskopischer Sphinkterotomie bei Patienten mit Gallenblase in situ. DMW - Deutsche Medizinische Wochenschrift. 113(13). 500–505.
7.
8.
9.
Dresemann, G., Mark Rosenthal, Klaus Hoeffken, et al.. (2007). Imatinib plus hydroxyurea versus hydroxyurea monotherapy in progressive glioblastoma (GBM) - An international open label randomised phase III study (ambrosia-study). Neuro-Oncology. 9(4). 2 indexed citations
10.
Dresemann, G., Christian Hosius, Zariana Nikolova, & Laurie Letvak. (2007). Single center phase II trial analysing the role of imatinib/hydroxyurea in patients (pts) with pretreated non-progressive glioblastoma (GBM) as maintenance treatment. Journal of Clinical Oncology. 25(18_suppl). 2055–2055. 2 indexed citations
11.
Dresemann, G., Christian Hosius, Zariana Nikolova, & Laurie Letvak. (2006). Imatinib plus hydroxyurea in pretreated non-progressive glioblastoma (GBM)—A single center phase II study. Journal of Clinical Oncology. 24(18_suppl). 1583–1583. 4 indexed citations
12.
13.
Dresemann, G.. (2005). Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Annals of Oncology. 16(10). 1702–1708. 132 indexed citations
14.
Reardon, David A., Merrill J. Egorin, Jennifer A. Quinn, et al.. (2005). Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme. Journal of Clinical Oncology. 23(36). 9359–9368. 243 indexed citations
15.
Dresemann, G.. (2004). Imatinib (STI571) plus hydroxyurea: Safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts). Journal of Clinical Oncology. 22(14_suppl). 1550–1550. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Badruddoja Breakdown of academic impact, for papers by Nathan De Beule Breakdown of academic impact, for papers by August J. Salvado Breakdown of academic impact, for papers by Koji Oka Breakdown of academic impact, for papers by Katharina Seystahl Breakdown of academic impact, for papers by Wolfgang Wick Breakdown of academic impact, for papers by Christopher J. Pirozzi Breakdown of academic impact, for papers by Candice A. Romany Breakdown of academic impact, for papers by Sandra H. E. Sprenger Breakdown of academic impact, for papers by Paulo Salazar
Rankless by CCL
2026